SKY-0515 Mid-Stage Signal Is Real But Uncontrolled — Pivotal Trials Are the Only Verdict That Matters

Skyhawk's RNA Splicing Pill Shows Positive 15-Month Data in Huntington's

Skyhawk Therapeutics announced final results from a small, mid-stage study of its once-daily RNA splicing pill, SKY-0515, for Huntington's disease. After 15 months, patients treated with SKY-0515 showed an average improvement of 0.94 points on a functional, cognitive, and movement assessment scale, which was 1.59 points better than an untreated natural history comparison group that declined by 0.65 points. The drug was well-tolerated with no serious adverse events, and a higher dose consistently reduced mutant huntingtin protein by over 60% and PMS1 messenger RNA by 25%. These positive outcomes have led Skyhawk to advance SKY-0515 into two larger late-stage clinical trials, one of which has completed enrollment.

• The study demonstrated that patients receiving SKY-0515 experienced an average improvement of 0.94 points on a comprehensive assessment scale over 15 months. This contrasted significantly with a natural history comparison group, which saw an average decline of 0.65 points, resulting in a 1.59-point difference favoring SKY-0515. These differences achieved statistical significance from the nine-month mark, suggesting a meaningful clinical benefit for patients.
• SKY-0515 showed a robust impact on key disease biomarkers. A higher dose of the drug consistently lowered mutant huntingtin protein, the primary driver of Huntington's disease, by more than 60%. Additionally, it reduced PMS1 messenger RNA levels by 25%. The drug exhibited a favorable safety profile, being generally well-tolerated with no serious adverse events reported throughout the 15-month treatment period.
• Following these promising mid-stage results, Skyhawk Therapeutics is progressing SKY-0515 into a late-stage program named FALCON, which includes two larger clinical trials. One trial has already completed enrollment with 144 participants with Stage 2 and Stage 3 Huntington’s disease across Australia and New Zealand, while a separate worldwide study aims to enroll approximately 600 participants, underscoring the company's commitment to further evaluate the drug's potential.

Understanding the Genetic Drivers of Huntington’s Disease

Huntington's disease (HD) is driven at its genetic core by an expanded CAG repeat in the huntingtin (HTT) gene, which encodes an abnormally elongated polyglutamine tract in the huntingtin (HTT) protein. This somatic CAG repeat mutation undergoes further expansion over time, and the degree of somatic expansion correlates with pathogenesis. Mismatch repair (MMR) proteins are central to this process: the MutSβ complex (MSH2-MSH3) promotes CTG and CAG repeat expansions by directly interfering with normal Okazaki fragment processing by flap endonuclease 1 (Rad27) and DNA ligase I (Cdc9), producing small, incremental expansion events during lagging-strand DNA replication. Downstream MLH complexes — Mlh1-Pms1, Mlh1-Mlh2, and Mlh1-Mlh3 — are also required for CAG expansions, with loss of Mlh1-Pms1 or Mlh1-Mlh2 exhibiting the strongest effects, and mutations in PMS1 and MLH3 acting synergistically. Mlh1 and Mlh3 have been identified as critical genetic modifiers of HTT CAG instability in mouse models, with MLH1 protein levels playing an important role in driving the efficiency of somatic expansions.

At the molecular level, mutant HTT (mHTT) disrupts multiple intracellular quality-control and signalling pathways. The ubiquitin-proteasome system (UPS) and autophagy system are disturbed differentially across tissues before disease onset, with UPS impairment observed in the cortex, striatum, liver, and lung, and autophagy disturbance prominent in heart and muscle. Transcriptional dysregulation is a further prominent hallmark: mHTT alters the interaction with RE1-silencing transcription factor (REST), a master repressor of neuronal gene expression, leading to elevated nuclear REST levels, increased RE1 occupancy, and repression of target genes including brain-derived neurotrophic factor (BDNF). REST also regulates transcription of regulatory microRNAs, many of which are dysregulated in HD, constituting a second, indirect mechanism by which REST alters the neuronal transcriptome. Additionally, BDNF normally confers neuroprotection by reducing toxic extrasynaptic NMDA receptor signalling through a nuclear calcium–inhibin β-A pathway; this process may be compromised in HD, where reduced BDNF levels and enhanced extrasynaptic NMDA receptor signalling contribute to mitochondrial dysfunction and excitotoxicity.

At the cellular level, mHTT accumulation drives dysfunction across neuronal and glial compartments. In neurons, mHTT is associated with impaired mitochondrial dynamics — including deficits in mitochondrial axonal transport and unbalanced fusion and fission processes — as well as increased intracellular calcium levels and dysfunctional mitochondrial membrane potential. Neuroinflammation mediated by activated microglia and reactive astrocytes further perpetuates HD pathology through transcriptional activation of pro-inflammatory genes, with reactive astrocytes additionally displaying functional changes in glutamate and ion homeostasis and energy metabolism. Mlh1 has also been identified as an enhancer of nuclear huntingtin accumulation in striatal neurons, linking the MMR-driven repeat expansion mechanism directly to the cellular pathology of neurodegeneration.

SKY-0515: Promising Efficacy and Safety in Mid-Stage Huntington’s Trial

Two recent clinical trials have evaluated NestaCell® (allogeneic human dental pulp stem cells, hDPSCs) in Huntington's disease. A Phase I, open-label, first-in-human study administered intravenous hDPSC infusions to six male patients across two dose cohorts — 1 million cells/kg and 2 million cells/kg — over up to five years, with a total of 4 to 26 infusions per patient. No adverse events occurred during 48-hour ICU monitoring or within 15 days post-infusion. Of 41 treatment-emergent adverse events (TEAEs) reported during follow-up, 35 were judged unrelated to hDPSCs. Six TEAEs were considered treatment-related, involving transient changes in hair pigmentation or regrowth. One patient discontinued due to lung cancer arising from a pre-existing pulmonary nodule; genetic analysis of the excised tumour showed no evidence of investigational product engraftment. Preliminary efficacy analyses indicated potential stabilisation of disease progression, particularly in the UHDRS Total Motor Score (TMS) and Total Functional Capacity (TFC).

Building on these findings, a Phase II randomised, double-blind, placebo-controlled trial enrolled 35 patients assigned at a 2:2:1 ratio to receive hDPSCs at 1 million cells/kg, 2 million cells/kg, or placebo across nine intravenous infusions over 11 months. The primary endpoint was UHDRS TMS change. Both doses demonstrated a favourable safety profile, with no increased incidence of adverse events compared to placebo and no serious adverse event deemed treatment-related. Both doses significantly improved UHDRS-TMS compared to placebo (p = 0.005), while the 2 million cells/kg group showed significant benefits in UHDRS-TFC (p = 0.011). Additional improvements were observed in the Total Chorea Score and Functional Checklist. MRI analysis indicated a non-significant trend toward neuroprotection, with slower central nervous system white and grey matter decline in treated patients.

A separate Phase II study evaluated triheptanoin — a drug targeting the Krebs cycle — in patients with early-stage Huntington's disease (UHDRS TMS between 5 and 40). The 6-month, double-blind, randomised controlled trial enrolled 100 patients (mean age 49 years, 52% women) and found no difference in caudate atrophy between groups at 6 months (mean caudate boundary shift integral 0.026 [95% CI 0.018–0.033] vs. 0.023 [0.014–0.032]), providing Class I evidence that triheptanoin does not slow caudate atrophy compared with placebo over 6 months. However, in a post-hoc comparison against an external placebo control group at 12 months, patients treated with triheptanoin for 12 months showed caudate atrophy decreased by approximately 50% (0.038 [0.028–0.048] vs. 0.070 [0.057–0.082]) and TMS stabilisation (0.66 [−1.07 to 2.48] vs. 2.65 [1.38–3.89]); the post-hoc nature of these findings is noted as a major limitation.

The Evolving Huntington’s Treatment Landscape and SKY-0515’s Future

The Huntington's disease treatment landscape has undergone meaningful stratification over the past several years, with symptomatic and disease-modifying approaches advancing along distinct trajectories. Among established symptomatic therapies, VMAT-2 inhibitors — tetrabenazine, deutetrabenazine, and valbenazine — have demonstrated significant improvement in motor outcomes versus placebo in randomized trials, with a pooled mean difference of -3.80 (95% CI -5.76 to -1.83) on the UHDRS Total Motor Score and -3.05 (95% CI -3.84 to -2.26) on the Total Maximal Chorea score. The Phase 3 KINECT-HD trial of valbenazine specifically reported a least-squares mean difference of -3.2 (95% CI -4.4 to -2.0; p<0.0001) in TMC score versus placebo, with somnolence as the most commonly reported treatment-emergent adverse event and no clinically important changes in vital signs, electrocardiograms, or laboratory tests. Dopamine stabilizers such as pridopidine and ordopidine have not demonstrated a statistically significant benefit on UHDRS TMS (MD -0.98, 95% CI -2.48 to 0.51), and Trial Sequential Analysis indicates that additional data are required before conclusions can be drawn about their effects or safety outcomes.

On the disease-modifying front, the field has experienced both setbacks and renewed momentum. The antisense oligonucleotide tominersen, designed to reduce mutant huntingtin (mHTT) protein via intrathecal administration, was prematurely halted after failing to demonstrate superiority over placebo and producing worsened outcomes at the highest doses. Pharmacokinetic-pharmacodynamic modelling across 915 participants subsequently clarified that the highest exposure quartile achieved 54% mHTT reduction at steady state but was associated with transient elevations in biomarkers of neuroinjury and inflammation, while the lowest exposure quartile achieved 24% mHTT reduction with a more favorable biomarker profile — findings that now inform dose selection in the GENERATION HD2 study. Separately, the small molecule branaplam has demonstrated mHTT protein lowering by promoting pseudoexon inclusion and nonsense-mediated decay of HTT mRNA in patient cells and mouse models, and optimized splicing modulators with a pyrazine amide core have shown CNS penetrance and oral bioavailability with significant HTT-lowering in human HD stem cells and BACHD mouse models.

Gene therapy and biomarker development have further reshaped the clinical development environment. AMT-130, a one-time AAV5-delivered microRNA therapy administered via stereotactic intracerebral infusion into the caudate and putamen, has shown broad vector distribution, sustained HTT mRNA reduction, and improved motor performance in preclinical large-animal and rodent models. Early Phase I/II clinical data indicate a favorable safety profile, reductions in neurofilament light chain (NfL) levels, and stabilization of motor and functional decline, particularly in high-dose cohorts. NfL itself has emerged as a central pharmacodynamic biomarker across this pipeline: plasma and CSF NfL concentrations are significantly elevated in HD mouse models from 9 months of age, and mHTT lowering initiated after the onset of neuropathological and behavioral phenotypes produces dose-dependent stabilization of NfL increases in both biofluids, supporting its use as an exploratory response biomarker. The FDA's approval of tofersen for SOD1-ALS based on NfL reduction has further reinforced regulatory receptivity to NfL as a surrogate marker, a precedent with direct relevance to ongoing HD programs.

Skyhawk's SKY-0515: A Promising Advance in Huntington's Disease

The recent announcement regarding Skyhawk Therapeutics' SKY-0515 marks a significant moment in the challenging quest for effective Huntington's disease (HD) treatments. With a devastating prognosis and limited therapeutic options, any development showing potential to slow or reverse disease progression is met with considerable anticipation. SKY-0515, an oral RNA splicing modulator, has demonstrated encouraging mid-stage results, including a notable functional improvement in patients and a substantial reduction in the mutant huntingtin protein (mHTT) that drives the disease. This dual impact on both clinical symptoms and the underlying pathology is a powerful signal, suggesting a potential disease-modifying effect.

The drug's once-daily oral administration offers a practical advantage for patients, potentially improving adherence and quality of life compared to more invasive therapies. The consistent reduction of mHTT by over 60% provides strong scientific validation for the RNA splicing mechanism, positioning it as a viable strategy in neurodegenerative drug development. This positive data has propelled SKY-0515 into two pivotal late-stage trials, one of which is already fully enrolled, indicating a rapid progression towards potential market entry.

However, the path forward is not without its complexities. While the mid-stage results are promising, the comparison to a natural history cohort rather than a concurrent placebo group means that the observed functional benefits require rigorous confirmation in the ongoing larger, randomized controlled trials. Furthermore, while mHTT reduction is a critical biomarker, the long-term durability and clinical significance of this reduction in a diverse patient population will be key to establishing SKY-0515's true value. The HD pipeline is also highly competitive, with other modalities like gene therapies and antisense oligonucleotides from companies such as uniQure and Roche also advancing. Skyhawk's ability to differentiate SKY-0515 based on its oral convenience, safety profile, and confirmed efficacy in late-stage studies will be crucial for its ultimate success in this evolving therapeutic landscape.